The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37-Targeted Radioimmunotherapy in Activated B Cell Like Diffuse Large B Cell Lymphoma Cell Lines

The CD37 targeting radioimmunoconjugate (177)Lu-lilotomab satetraxetan (Betalutin) is currently being evaluated in a clinical phase 2b trial for patients with follicular lymphoma (FL) and in a phase 1 trial for patients with diffuse large B-cell lymphoma (DLBCL). Herein we have investigated the effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Rødland, Gro Elise, Melhus, Katrine, Generalov, Roman, Gilani, Sania, Bertoni, Francesco, Dahle, Jostein, Syljuåsen, Randi G., Patzke, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6897291/
https://www.ncbi.nlm.nih.gov/pubmed/31850205
http://dx.doi.org/10.3389/fonc.2019.01301

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6897291/
https://www.ncbi.nlm.nih.gov/pubmed/31850205
http://dx.doi.org/10.3389/fonc.2019.01301

Ejemplares similares